Main Conference: 27 - 29 May 2026 | Basel, Switzerland
ADCs & Bioconjugate Track
Accelerating Antibody‑Drug Conjugate Innovation from Discovery to Clinical Impact
Why Attend the ADCs & Bioconjugates Track?
ADCs are among the most complex and promising biologic modalities in development today. Success depends on integrating antibody engineering, chemistry, payload design, pharmacology, and clinical strategy.
This track is designed to help you:
Who Should Attend?
What This Track Covers
The co-located ADCs & Bioconjugates Track delivers over 3 full days of content, including keynotes, 30+ speakers and 5 half-day sessions, each featuring 6 expert speakers from leading pharmaceutical companies, biotech innovators, and academic research institutions.
ADC's – A Maturing Field or Still Room for Disruption?
Novel Payload and Linker Technologies
Innovative Antibody Formats and Payload Combinations
Breakthrough Innovations and New Modalities for Bioconjugates
Advancing ADCs to the Clinic
Session Spotlight
Perspectives on Antibody-Drug Conjugates
Wednesday 27th May 2026 09:05am
Peter Senter, PhD, Co-Founder and CSO at Atida Bio
Discovery and Developments of ADCs
Wednesday 27th May 2026 10:20am
Gail Lewis, PhD, Distinguished Scientist, Discovery Oncology at Genentech
Meet ADC and Bioconjugates Leaders
Hear from the senior scientists and academic pioneers advancing the next generation of ADC and bioconjugate technologies.
This track is specifically designed for professionals who:
- Are developing or optimising ADC or bioconjugate programmes
- Work at the interface of antibody engineering and chemistry
- Need to improve therapeutic index, safety, or clinical translation
- Want to understand why some ADCs succeed while others fail
- Are responsible for strategic R&D or pipeline decisions